Avalo Therapeutics advances AVTX-010 for hidradenitis suppurativa

Avalo Therapeutics Inc. is advancing AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody with potential for hidradenitis suppurativa and additional inflammatory disorders